Early Growth Response 1 Deficiency Protects the Host against Pseudomonas aeruginosa Lung Infection

Zheng Pang1, Renee Raudonis2, Craig McCormick2

  • 1Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.

Infection and Immunity
|October 16, 2019
PubMed

Insights

Early growth response 1 (Egr-1) surprisingly hinders host defense against Pseudomonas aeruginosa lung infections. Mice lacking Egr-1 showed reduced inflammation and better bacterial clearance, highlighting Egr-1

Area of Science:

  • Immunology
  • Microbiology
  • Molecular Biology

Background:

  • Pseudomonas aeruginosa is a major cause of hospital-acquired infections, with immune response mechanisms not fully understood.
  • Early growth response 1 (Egr-1), a transcription factor, regulates inflammatory responses.
  • The specific role of Egr-1 in host defense against P. aeruginosa pneumonia requires further elucidation.

Purpose of the Study:

  • To investigate the function of Egr-1 in the host immune response during acute Pseudomonas aeruginosa lung infection.
  • To determine the impact of Egr-1 deficiency on inflammation, bacterial clearance, and immune cell function.

Main Methods:

  • Utilized a mouse model of acute bacterial pneumonia induced by P. aeruginosa.
  • Assessed Egr-1 expression levels post-infection.
  • Analyzed mortality rates, cytokine profiles, NF-κB activation, chemokine production, nitric oxide levels, and bacterial burden in Egr-1-deficient and wild-type mice.

Main Results:

  • Egr-1 expression was transiently induced during P. aeruginosa infection.
  • Egr-1-deficient mice exhibited reduced mortality, lower pro-inflammatory cytokine levels (TNF, IL-1β, IL-6, IL-12, IL-17), and enhanced bacterial clearance.
  • Egr-1 deficiency led to decreased NF-κB activation, altered chemokine profiles, increased nitric oxide production, and improved bacterial killing by macrophages and neutrophils.

Conclusions:

  • Egr-1 plays a detrimental role in host defense against P. aeruginosa acute lung infection.
  • Egr-1 promotes systemic inflammation and impairs nitric oxide production, which is crucial for bacterial clearance.
  • Targeting Egr-1 may represent a therapeutic strategy to enhance host defense against P. aeruginosa infections.